Squarepoint’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $588K | Sell |
422,828
-800,199
| -65% | -$1.1M | ﹤0.01% | 3203 |
|
|
2025
Q4 | $1.97M | Buy |
1,223,027
+444,498
| +57% | +$931K | ﹤0.01% | 2077 |
|
|
2025
Q3 | $2.13M | Buy |
778,529
+617,337
| +383% | +$2.05M | ﹤0.01% | 2049 |
|
|
2025
Q2 | $587K | Buy |
161,192
+116,149
| +258% | +$319K | ﹤0.01% | 3132 |
|
|
2025
Q1 | $86.5K | Buy |
+45,043
| New | +$91.9K | ﹤0.01% | 4258 |
|
|
2024
Q4 | – | Sell |
-140,167
| Closed | -$185K | – | 4983 |
|
|
2024
Q3 | $185K | Buy |
140,167
+101,612
| +264% | +$136K | ﹤0.01% | 3713 |
|
|
2024
Q2 | $39.3K | Sell |
38,555
-216,109
| -85% | -$267K | ﹤0.01% | 3934 |
|
|
2024
Q1 | $466K | Buy |
254,664
+224,108
| +733% | +$358K | ﹤0.01% | 3096 |
|
|
2023
Q4 | $37.9K | Buy |
+30,556
| New | +$31.2K | ﹤0.01% | 3873 |
|
|
2022
Q3 | – | Sell |
-29,471
| Closed | -$10K | – | 2943 |
|
|
2022
Q2 | $10K | Sell |
29,471
-28,825
| -49% | -$12.1K | ﹤0.01% | 2789 |
|
|
2022
Q1 | $42K | Buy |
58,296
+32,044
| +122% | +$68.6K | ﹤0.01% | 2683 |
|
|
2021
Q4 | $59K | Buy |
+26,252
| New | +$71.6K | ﹤0.01% | 3004 |
|
|
2021
Q2 | – | Sell |
-238,876
| Closed | -$809K | – | 3182 |
|
|
2021
Q1 | $809K | Sell |
238,876
-179,904
| -43% | -$648K | ﹤0.01% | 1672 |
|
|
2020
Q4 | $1.17M | Sell |
418,780
-606,616
| -59% | -$1.77M | 0.01% | 1216 |
|
|
2020
Q3 | $2.57M | Buy |
1,025,396
+931,780
| +995% | +$8.18M | 0.03% | 553 |
|
|
2020
Q2 | $1.27M | Sell |
93,616
-127,493
| -58% | -$1.32M | 0.02% | 815 |
|
|
2020
Q1 | $1.68M | Buy |
221,109
+107,989
| +95% | +$840K | 0.04% | 507 |
|
|
2019
Q4 | $715K | Sell |
113,120
-53,404
| -32% | -$254K | ﹤0.01% | 1546 |
|
|
2019
Q3 | $653K | Sell |
166,524
-118,521
| -42% | -$508K | 0.01% | 1476 |
|
|
2019
Q2 | $1.38M | Buy |
285,045
+174,503
| +158% | +$993K | 0.01% | 1068 |
|
|
2019
Q1 | $905K | Sell |
110,542
-47,463
| -30% | -$326K | 0.01% | 1156 |
|
|
2018
Q4 | $874K | Buy |
158,005
+73,142
| +86% | +$572K | 0.01% | 979 |
|
|
2018
Q3 | $749K | Buy |
84,863
+4,683
| +6% | +$41.9K | 0.01% | 1124 |
|
|
2018
Q2 | $800K | Buy |
80,180
+28,380
| +55% | +$284K | 0.01% | 979 |
|
|
2018
Q1 | $494K | Buy |
51,800
+13,996
| +37% | +$196K | 0.01% | 1096 |
|
|
2017
Q4 | $562K | Buy |
+37,804
| New | +$627K | 0.01% | 1138 |
|
|
2017
Q1 | – | Sell |
-18,462
| Closed | -$192K | – | 1497 |
|
|
2016
Q4 | $192K | Buy |
+18,462
| New | +$159K | 0.01% | 1457 |
|
Other funds holding AKBA
VCM
VPM
Squarepoint's AKBA Position: Q1 2026 in Review
Squarepoint reduced its Akebia Therapeutics (AKBA) stake by 65% in Q1 2026, selling an estimated $1.1M and leaving 422,828 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #3203.
Squarepoint first reported a position in AKBA in Q4 2016 and has held it in 27 quarters since. The position peaked at $2.57M in Q3 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Squarepoint held 422,828 shares of Akebia Therapeutics worth $588K as of Q1 2026.
- Squarepoint sold 800,199 Akebia Therapeutics shares in Q1 2026, an estimated $1.1M.
- Akebia Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3203 holding.
- Squarepoint first reported a position in Akebia Therapeutics in Q4 2016 and has held it in 27 quarters since.
- Squarepoint's Akebia Therapeutics position peaked at $2.57M in Q3 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.